ÚHKT - Ústav hematologie a krevní transfuze
Úsek pro vědu a výzkum

List of Active Studies

EU Trial Number

Protocol Number

Diagnoses

Study Description

Principal Investigator

Coordinator

Recruitment

PHASE 1

Eudra CT
2024-510815-30-00

UHKT-CAR19-01, NCT05054257

B-ALL,
B-NHL

Clinical evaluation of the safety and efficacy of autologous CART19 lymphocytes in patients with relapsed or refractory acute B-lymphoblastic leukemia (B-ALL) or relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). Open Phase I study with dose escalation.

MUDr. Jan Vydra, Ph.D.
jan.vydra@uhkt.cz

Mgr. Tereza Brabencová
Tereza.Brabencova@uhkt.cz

Kateřina Waldmannová
Katerina.Waldmannova@uhkt.cz

yes

EU CT
2022-503165-30-00

UHKT-CAR123-01, NCT06765876

CD123+/ AML, ALL, MDS-IB2, BPDCN

Safety and efficacy of autologous CART123 lymphocytes in patients with relapsed or refractory CD123 positive hematologic malignancy. Open Phase I study with dose escalation.

MUDr. Jan Vydra, Ph.D.
jan.vydra@uhkt.cz

Mgr. Tereza Brabencová
Tereza.Brabencova@uhkt.cz

Kateřina Waldmannová
Katerina.Waldmannova@uhkt.cz

yes

EU CT 
2024-517681-41
IM060-0001 SLE, SSc, IIM, RA Phase 1, multicenter, open-label study of BMS-986515, from healthy donors allogeneic CD19-targeted chimeric antigen receptor (CAR) T cells, in participants with severe, refractory autoimmune diseases
Study in cooperation with the Institute of Rheumatology as a referring center.

 

MUDr. Ladislav Šenolt, Ph.D. (IR)

MUDr. Jan Vydra, Ph.D. (ÚHKT)
jan.vydra@uhkt.cz

Ing. Anna Dobrovolná
Anna.Dobrovolna@uhkt.cz

Bc. Michaela Kosternová
Michaela.Kosternova@uhkt.cz
yes

PHASE 1/2

EU CT
2024-515034-33

AZDO486 — D7407C00001

CLL

Open multicenter Phase I/II master protocol to evaluate the safety and efficacy of AZD0486 as monotherapy or in combination with other anticancer agents in participants with mature B-cell malignancies.

MUDr. Robert Pytlík, Ph.D.
Robert.Pytlik@uhkt.cz
Bc. Michaela Kosternová
Michaela.Kosternova@uhkt.cz
yes
  UHKT-PTC-TMI-01 AML, MDS Proton radiotherapy of bone marrow (Total Marrow Irradiation) as part of
preparatory regimen prior to allogeneic hematopoietic stem cell transplantation in patients with high-risk
acute myeloid leukemia or myelodysplastic syndrome. Phase I/II pilot study.
doc. MUD